[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors]

Melanoma and Skin Cancer

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Melanoma Res.

Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C

doi: 10.1097/CMR.0000000000000703.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Melanoma Res.

Thummalapalli R, Melms JC, Mier J, Izar B

doi: 10.1097/CMR.0000000000000646.

Melanoma and Skin Cancer

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Melanoma Res.

Kosche C, Stout M, Sosman J, Lukas RV, Choi JN

doi: 10.1097/CMR.0000000000000642.

Melanoma and Skin Cancer

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Melanoma Res.

Hanna DL, Law SJ, Merrick SA, Heptinstall L, Bass P, Dupont P, Sheri A

doi: 10.1097/CMR.0000000000000651.

Melanoma and Skin Cancer

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Br J Dermatol.

Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N

doi: 10.1111/bjd.19750.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin CancerVitiligo

Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

JAMA Dermatol

Nakamura Y, Teramoto Y, Asami Y, Matsuya T, Adachi JI, Nishikawa R, Yamamoto A

doi: 10.1001/

Melanoma and Skin Cancer

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

BMC Cancer.

Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T

doi: 10.1186/s12885-017-3785-4.

Melanoma and Skin Cancer

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

Melanoma Res.

Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG, Swick B

doi: 10.1097/CMR.0000000000000713.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

Paraneoplastic neutrophilic leukemoid reaction in a melanoma patient: association between tumour volume and leukocytosis

Br J Dermatol.

Fredeau L, Bohelay G, Shourick J, Piver D, Guyot A, -H Schlageter M, Caux F, Maubec E

doi: 10.1111/bjd.19059.

Related content

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

Paraneoplastic neutrophilic leukemoid reaction in a melanoma patient: association between tumour volume and leukocytosis